Pulse Biosciences (PLSE) Net Equity Issued and Repurchased (2016 - 2022)

Pulse Biosciences' Net Equity Issued and Repurchased history runs 6 years deep, the most recent figure standing at -$29000.0 for Q4 2022.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$29000.0 in Q4 2022; TTM through Dec 2023 was -$99000.0, a 101.2% decrease from a year earlier, with the FY2022 full-year figure at $14.9 million, down 73.78% from the prior year.
• Net Equity Issued and Repurchased climbed to -$29000.0 in Q4 2022 per PLSE's latest filing, from -$70000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $29.5 million in Q2 2020 and bottomed at -$261000.0 in Q3 2020.
• The 4-year median for Net Equity Issued and Repurchased is $263500.0 (2019), against an average of $5.1 million.
• Across the five-year window, Net Equity Issued and Repurchased soared 3298.85% in 2021 and slumped 100.84% in 2022, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $272000.0 in 2019, then sank by 123.53% to -$64000.0 in 2020, then soared by 13145.31% to $8.3 million in 2021, then slumped by 100.35% to -$29000.0 in 2022.
• Per Business Quant, the three latest PLSE Net Equity Issued and Repurchased figures stand at -$29000.0 (Q4 2022), -$70000.0 (Q3 2022), and $8.3 million (Q3 2021).